600521 Stock Overview
Zhejiang Huahai Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 4/6 |
Zhejiang Huahai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥16.75 |
52 Week High | CN¥19.10 |
52 Week Low | CN¥10.71 |
Beta | 0.12 |
1 Month Change | 28.95% |
3 Month Change | 45.91% |
1 Year Change | -11.42% |
3 Year Change | -16.12% |
5 Year Change | 28.49% |
Change since IPO | 613.44% |
Recent News & Updates
Shareholder Returns
600521 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 4.4% | 2.7% | 1.2% |
1Y | -11.4% | -10.9% | -12.6% |
Return vs Industry: 600521 matched the CN Pharmaceuticals industry which returned -10.9% over the past year.
Return vs Market: 600521 exceeded the CN Market which returned -12.6% over the past year.
Price Volatility
600521 volatility | |
---|---|
600521 Average Weekly Movement | 5.6% |
Pharmaceuticals Industry Average Movement | 7.3% |
Market Average Movement | 8.5% |
10% most volatile stocks in CN Market | 12.5% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 600521's share price has been volatile over the past 3 months.
Volatility Over Time: 600521's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 7,682 | Bao Hua Chen | www.huahaipharm.com |
Zhejiang Huahai Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as high-density polyethylene bottles and polypropylene caps for pharmaceuticals.
Zhejiang Huahai Pharmaceutical Co., Ltd. Fundamentals Summary
600521 fundamental statistics | |
---|---|
Market cap | CN¥24.65b |
Earnings (TTM) | CN¥928.37m |
Revenue (TTM) | CN¥8.75b |
26.6x
P/E Ratio2.8x
P/S RatioIs 600521 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
600521 income statement (TTM) | |
---|---|
Revenue | CN¥8.75b |
Cost of Revenue | CN¥3.54b |
Gross Profit | CN¥5.21b |
Other Expenses | CN¥4.28b |
Earnings | CN¥928.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.63 |
Gross Margin | 59.59% |
Net Profit Margin | 10.61% |
Debt/Equity Ratio | 96.2% |
How did 600521 perform over the long term?
See historical performance and comparison